Cencora, Inc. reported a revenue of $85.9 million for the three months ending December 31, 2025, marking a 5.5% increase from $81.5 million in the same period of the previous year. The company's net income rose to $566.1 million, up from $493.7 million, resulting in earnings per share of $2.88, compared to $2.52 in the prior year. The increase in revenue and profitability was attributed to growth in both the U.S. Healthcare Solutions and International Healthcare Solutions segments, with the U.S. segment alone generating $76.2 million, a 5.0% increase year-over-year.

The financial performance reflects significant operational changes, including the acquisition of Retina Consultants of America (RCA) in January 2025, which contributed to a $428.8 million increase in gross profit for the U.S. Healthcare Solutions segment. However, total operating expenses also increased by 24.8% to $2.3 billion, primarily due to the RCA acquisition and an impairment of assets related to the U.S. Consulting Services business. The company recorded a goodwill impairment of $249.5 million during this quarter.

Cencora's operational metrics showed a notable increase in customer engagement, with a rise in accounts receivable and inventories, which contributed to $2.3 billion in cash used in operations. The company reported a total of 194.5 million shares outstanding as of January 31, 2026, with a cash dividend declared of $0.60 per share, up from $0.55 in the previous year. The company also maintained a strong cash position, with cash and cash equivalents totaling $1.8 billion at the end of the reporting period.

Looking ahead, Cencora anticipates continued revenue growth driven by market trends, including increased demand for specialty pharmaceuticals and the introduction of new therapies. However, the company also faces challenges such as potential changes in customer contracts and ongoing litigation related to opioid distribution, with an accrued litigation liability of $4.3 billion expected to be paid over the next 13 years. The company remains committed to managing its growth and operational efficiency while navigating the complexities of the healthcare landscape.

About Cencora, Inc.

Cencora is a leading global pharmaceutical sourcing and distribution company serving healthcare providers and manufacturers. It offers distribution of brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and related services. The company supports patient access, supply chain efficiency, and market development through logistics, consulting, and value-added solutions across the U.S. and international markets, focusing on healthcare providers, biotech firms, and animal health sectors.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.